The Brazilian Interdisciplinary AIDS Association (ABIA), a non-governmental organisation (NGO) has joined Indian patient groups in opposing a patent application for Tenofovir (commonly known as Viread), a key AIDS drug marketed by Gilead Sciences in India. This is the first time a foreign patient group has decided to oppose an Indian patent application on the grounds that an India patent would have a direct impact on Brazil's chances to produce and access affordable generic versions of the drug... Civil society groups have also filed an opposition to Gilead's patent application in Brazil.